1. Home
  2. PRAX vs VICR Comparison

PRAX vs VICR Comparison

Compare PRAX & VICR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$318.80

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Vicor Corporation

VICR

Vicor Corporation

HOLD

Current Price

$313.82

Market Cap

8.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
VICR
Founded
2015
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
8.1B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
PRAX
VICR
Price
$318.80
$313.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
3
Target Price
$572.13
$217.50
AVG Volume (30 Days)
560.5K
652.5K
Earning Date
05-08-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1764.29
EPS
N/A
0.44
Revenue
N/A
$452,701,000.00
Revenue This Year
N/A
$37.01
Revenue Next Year
$7,758.26
$39.47
P/E Ratio
N/A
$753.73
Revenue Growth
N/A
26.08
52 Week Low
$37.25
$41.76
52 Week High
$366.52
$369.40

Technical Indicators

Market Signals
Indicator
PRAX
VICR
Relative Strength Index (RSI) 56.63 51.36
Support Level $308.40 $241.14
Resistance Level $327.65 $361.89
Average True Range (ATR) 17.85 24.28
MACD 8.50 -0.97
Stochastic Oscillator 81.53 49.13

Price Performance

Historical Comparison
PRAX
VICR

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About VICR Vicor Corporation

Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others. The principal markets for the Company's power converters and systems are large original equipment manufacturers (OEMs), original design manufacturers (ODMs) and their contract manufacturers, and smaller, lower volume users, which are broadly distributed across several market areas.

Share on Social Networks: